Cargando…
Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial
BACKGROUND: N-acetyl cysteine (NAC) is a glutathione precursor that has been shown to have antidepressant efficacy in a placebo-controlled trial. The current study aimed to investigate the maintenance effects of NAC following eight weeks of open-label treatment for bipolar disorder. METHOD: The effi...
Autores principales: | Berk, Michael, Dean, Olivia M, Cotton, Sue M, Gama, Clarissa S, Kapczinski, Flavio, Fernandes, Brisa, Kohlmann, Kristy, Jeavons, Susan, Hewitt, Karen, Moss, Kirsteen, Allwang, Christine, Schapkaitz, Ian, Cobb, Heidi, Bush, Ashley I, Dodd, Seetal, Malhi, Gin S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482580/ https://www.ncbi.nlm.nih.gov/pubmed/22891797 http://dx.doi.org/10.1186/1741-7015-10-91 |
Ejemplares similares
-
Mixed Methods Thematic Analysis of a Randomised Controlled Trial of Adjunctive Mitochondrial Agents for Bipolar Depression
por: Russell, Samantha E., et al.
Publicado: (2022) -
Does Post-traumatic Stress Disorder Impact Treatment Outcomes within a Randomised Controlled Trial of Mitochondrial Agents for Bipolar Depression?
por: Russell, Samantha E., et al.
Publicado: (2023) -
Future Directions for Pharmacotherapies for Treatment-resistant Bipolar
Disorder
por: Dodd, Seetal, et al.
Publicado: (2015) -
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo
por: Berk, Michael, et al.
Publicado: (2019) -
Correction to: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo
por: Berk, Michael, et al.
Publicado: (2019)